Everything you need to know about TMS Around the World: How Europe and the US Approach Brain Stimulation Differently — how it works, what it costs, and how to find a provider who actually knows what they're doing.
The TMS Patient Buyer's Guide
Free 22-page guide — questions to ask, red flags, and how to choose the right provider.
Transcranial magnetic stimulation is one of the most internationally collaborative areas of clinical neuroscience, with research spanning continents and regulatory frameworks converging around shared scientific evidence. Yet significant differences exist in how TMS is practiced in Europe versus the United States. Understanding these differences illuminates broader themes in healthcare regulation, insurance coverage, and the translation of research into clinical practice.
Regulatory Frameworks
United States: FDA Clearance
In the United States, TMS devices are regulated as medical devices by the Food and Drug Administration (FDA). The FDA has cleared TMS for:
- Major Depressive Disorder (first cleared in 2008) — in adults who have not responded to at least one antidepressant; one device is also cleared as an adjunct for ages 15-21 (2024)
- Obsessive-Compulsive Disorder (2018, BrainsWay Deep TMS)
- Smoking cessation (2020, BrainsWay Deep TMS)
- Anxious depression / comorbid anxiety symptoms in depression (2021, BrainsWay Deep TMS)
- Migraine (single-pulse TMS devices)
The FDA clearance pathway requires demonstration of safety and efficacy through clinical trials. Off-label uses (conditions not specifically cleared) are permitted but are often not covered by insurance.
Europe: CE Mark
In the European Union, TMS devices require CE marking under the Medical Device Regulation (MDR). The CE mark indicates compliance with EU safety and performance requirements. Unlike the FDA’s indication-specific clearance, CE marking certifies a device for its manufacturer-stated intended purpose under EU rules, and national healthcare systems then set their own clinical and reimbursement policies. The details differ by country.
This difference has significant practical implications:
- Practice can vary by country and clinic — clinical use is guided by national guidelines and individual clinicians, and protocols may be less standardized than in the US
- Off-label use occurs in both regions — TMS for conditions without strong evidence is offered in the US as well as in Europe
Insurance Coverage
United States: Variable and Restrictive
Insurance coverage for TMS in the US is inconsistent and often restrictive:
Medicare coverage is set by regional Medicare contractors through Local Coverage Determinations (LCDs). Generally, Medicare covers TMS for:
- Treatment-resistant major depression that has not responded to antidepressant treatment (regional LCDs describe the required antidepressant history and, in at least one LCD, an adequate trial of evidence-based psychotherapy; see LCD L33398)
- Patients who cannot tolerate medications
- Treatment under physician supervision by a qualifying provider
Medicaid coverage varies by state.
Private insurers have highly variable policies:
- Most require prior authorization
- Many impose strict medication-failure criteria
- Coverage may be limited to specific devices
- Out-of-network access is often restricted
A typical course is around 36 sessions; out-of-pocket costs depend on your plan.
Europe: More Comprehensive but Variable
European coverage patterns vary by country and healthcare system:
Nationalized systems (UK NHS, German GKV):
- Availability and funding of TMS for depression varies by country and region
- Access often requires specialist referral
- In the UK, NICE guidance (2015) says the evidence on rTMS for depression raises no major safety concerns and that it can be used with normal arrangements for clinical governance
Social insurance systems (Germany, France, Netherlands):
- Coverage rules differ by country and by insurer
- Check national guidance for current reimbursement status
Private systems:
- Coverage depends on the individual insurer
- More flexibility in protocol selection
The variation in European coverage reflects different healthcare system structures, economic constraints, and national policies toward neuromodulation.
Clinical Practice Differences
Treatment Protocols
Both regions use similar core protocols, but emphasis differs:
United States:
- Standardization around FDA-cleared protocols
- Increasing use of theta burst (iTBS) following FDA clearance
- Strong emphasis on treatment resistance criteria
- Typical course: 36 sessions over 6-9 weeks
Europe:
- More variation in protocols based on individual clinician preference
- Earlier adoption of novel approaches (accelerated protocols, personalized targeting)
- Shorter treatment courses in some centers
- Greater use of maintenance and booster protocols
Provider Landscape
United States:
- TMS typically administered by technicians under physician supervision
- Physician oversight may be remote (telemedicine supervision)
- Clinic chains have expanded access
- Many academic medical centers offer TMS
Europe:
- TMS often administered by physicians directly
- More academic medical center-based treatment
- Smaller clinic networks
- Greater involvement of clinical neurophysiologists
Access and Availability
United States:
- Concentration in urban areas
- Rural access remains limited
- Wait times may be weeks to months
Europe:
- Wide variation by country
- Rural access is also challenging in many areas
Research Priorities
United States Focus Areas
American TMS research emphasizes:
Clinical effectiveness — Large pragmatic trials comparing TMS to standard treatments in real-world settings
Novel indications — PTSD, bipolar depression, addiction, chronic pain
Protocol optimization — Accelerated protocols, personalized targeting, maintenance strategies
Implementation science — How to expand access and integrate TMS into healthcare systems
Industry-sponsored research — Major TMS device companies fund clinical trials for new indications
European Focus Areas
European research tends to emphasize:
Basic neuroscience — Understanding mechanisms of TMS at the synaptic and network level
Personalized medicine — Using neuroimaging to guide treatment selection and targeting
Novel coil development — Engineering advances in targeting and depth penetration
Regulatory science — Contributing to EU regulatory frameworks for brain stimulation
International collaboration — European multi-center trials leverage diverse healthcare systems
Key Differences Summarized
| Aspect | United States | Europe |
|---|---|---|
| Regulation | FDA indication-specific clearance | CE marking (device-level) |
| Coverage | Varies by insurer and Medicare region | Varies by country |
| Clinical protocols | Standardized around FDA protocols | More protocol variation |
| Research focus | Clinical effectiveness, new indications | Mechanisms, personalized targeting |
| Access | Concentrated in urban areas | Variable by country |
| Provider model | Technician-administered | Physician-administered |
Cross-Atlantic Learning
Both regions have lessons to offer:
From Europe:
- Clinical flexibility and strong academic research traditions
- Physician-administered treatment may allow better protocol individualization
From the United States:
- The benefits of defined FDA clearance for establishing treatment credibility
- Large-scale clinical effectiveness research
- The TMS clinic chain model for expanding access
The Future
Global TMS practice is converging:
- International guidelines from the International Federation of Clinical Neurophysiology (IFCN) provide shared safety and efficacy recommendations
- Global clinical trials continue to generate evidence on where TMS helps
- Telehealth may help equalize access across both regions
*For patients considering TMS, understanding the international landscape can inform expectations and help identify optimal treatment options, *
Related reading
- TMS for Multiple Sclerosis: Addressing Fatigue, Depression, and Cognitive Impairment
- What TMS Actually Feels Like: A Session-by-Session Guide
- How to Prepare for Your First TMS Session
- Preparing for Your First TMS Session: A Practical Walkthrough
- TMS for anxiety
- TMS for Treatment-Resistant Depression: What Patients Need to Know
